4//SEC Filing
GALECTIN THERAPEUTICS INC 4
Accession 0001179022-15-000085
$GALTCIK 0001133416operating
Filed
Jul 7, 8:00 PM ET
Accepted
Jul 8, 4:58 PM ET
Size
17.0 KB
Accession
0001179022-15-000085
Insider Transaction Report
Form 4
Martin Rod D
Director10% Owner
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2015-04-08−7,408→ 0 totalExercise: $6.48Exp: 2016-03-24→ Common Stock (7,408 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-04-08−6,780→ 0 totalExercise: $7.08Exp: 2021-06-28→ Common Stock (6,780 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-04-08−5,204→ 0 totalExercise: $13.38Exp: 2024-01-21→ Common Stock (5,204 underlying) - Disposition to Issuer
Stock Option (right to buy)
2015-04-08−16,714→ 0 totalExercise: $3.59Exp: 2023-03-28→ Common Stock (16,714 underlying) - Award
Common Stock
2015-04-08+26,395→ 202,089 total - Award
Common Stock
2015-03-12+1,784→ 176,606 total
Holdings
- 2,776,186(indirect: By 10X Fund L.P.)
Common Stock
Footnotes (7)
- [F1]Amount reported includes shares acquired on May 13, 2015 and previously reported on a Form 4 filed on May 15, 2015.
- [F2]Reporting person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Martin disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F3]The option vested quarterly in eight equal installments beginning May 12, 2011.
- [F4]The option was canceled by mutual agreement of the reporting person and Galectin Therapeutics, Inc. The reporting person received 26,395 shares of restricted common stock, reported in Table 1 of this Form 4, as consideration for the cancellation of options granted on March 24, 2011, June 28, 2011, March 28, 2013 and January 21, 2014.
- [F5]The option vested as to one-eighth of the shares on June 28, 2011 and thereafter quarterly in seven equal installments beginning August 12, 2011.
- [F6]The option vested quarterly in eight equal installments beginning on May 12, 2013.
- [F7]25% of the options vested on January 21, 2014, the grant date, with the remainder vesting ratably on a monthly basis over a three year period.
Documents
Issuer
GALECTIN THERAPEUTICS INC
CIK 0001133416
Entity typeoperating
IncorporatedNV
Related Parties
1- filerCIK 0001133416
Filing Metadata
- Form type
- 4
- Filed
- Jul 7, 8:00 PM ET
- Accepted
- Jul 8, 4:58 PM ET
- Size
- 17.0 KB